Nanotechnology and COVID-19 mRNA Vaccines

Authors

  • Mohsen Mehrabi - Assistant Professor of Medical Nanotechnology, School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran.2- Editor of Knowledge and Health in Basic Sciences Journal. orcid http://orcid.org/0000-0002-9891-4964

DOI:

https://doi.org/10.22100/jkh.v16i3.2768

Abstract

Today, nanotechnology has been studied in various fields of science. The field of vaccines is one of the areas that is being more attention today due to the COVID-19 pandemic (1). Nanoparticles can play both an adjuvant and a delivery roles in vaccine systems and also nanotechnology-based vaccines can stimulate both the humoral and cell-mediated immune responses (2). There are several companies involved in the production of Covid 19 vaccine, two of which, Pfizer-BioNTech and Moderna, have been able to produce vaccines based on nanotechnology and mRNA. The above-mentioned companies have used lipid nanoparticles as a vaccine delivery system in their formulations. The lipid nanoparticles promote endosomal escape, prevention of enzymatic degradation and release their genetic cargo in the cytosol, where the mRNA is translated into proteins that can play an antigenic role and stimulate the immune system. The success of Pfizer-BioNTech (BNT162b2) and Moderna (mRNA-1273) vaccines with ~95% efficacy in phase III clinical trials can be attributed to their especial nanocarrier, the "lipid nanoparticles"(3-5).

Author Biography

  • Mohsen Mehrabi, - Assistant Professor of Medical Nanotechnology, School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran.2- Editor of Knowledge and Health in Basic Sciences Journal.
     

Published

2021-10-26

Issue

Section

Editorial

How to Cite

Nanotechnology and COVID-19 mRNA Vaccines. (2021). Knowledge and Health in Basic Medical Sciences, 16(3), Page:1-1. https://doi.org/10.22100/jkh.v16i3.2768

Most read articles by the same author(s)

<< < 3 4 5 6 7 8 9 10 11 12 > >>